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Liver biology and function, drug-induced liver injury (DILI) and liver diseases are difficult to study using 
current in vitro models such as primary human hepatocyte (PHH) monolayer cultures, as their rapid 
de-differentiation restricts their usefulness substantially. Thus, we have developed and extensively 
characterized an easily scalable 3D PHH spheroid system in chemically-defined, serum-free conditions. 
Using whole proteome analyses, we found that PHH spheroids cultured this way were similar to the 
liver in vivo and even retained their inter-individual variability. Furthermore, PHH spheroids remained 
phenotypically stable and retained morphology, viability, and hepatocyte-specific functions for culture 
periods of at least 5 weeks. We show that under chronic exposure, the sensitivity of the hepatocytes 
drastically increased and toxicity of a set of hepatotoxins was detected at clinically relevant 
concentrations. An interesting example was the chronic toxicity of fialuridine for which hepatotoxicity 
was mimicked after repeated-dosing in the PHH spheroid model, not possible to detect using previous 
in vitro systems. Additionally, we provide proof-of-principle that PHH spheroids can reflect liver 
pathologies such as cholestasis, steatosis and viral hepatitis. Combined, our results demonstrate that 
the PHH spheroid system presented here constitutes a versatile and promising in vitro system to study 
liver function, liver diseases, drug targets and long-term DILI.
The liver is a vital organ for synthesis, metabolism and detoxification, but liver diseases and drug-induced liver 
injury (DILI) can severely impair liver functionality. To study liver biology and function, drug-induced hepato-
toxicity and liver diseases, primary human hepatocytes (PHH) are currently considered as the gold standard in 
vitro model system1. However, when maintained in conventional 2D monolayer cultures, PHH de-differentiate 
and rapidly lose hepatocyte-specific functions2–4. Thus, the utility of conventional 2D PHH cultures for the 
long-term study of liver biology and assays that require liver-specific functionalities is largely impaired. There 
is therefore a need for more faithful in vitro models which more accurately reflect in vivo liver biology. To this 
end, new systems are needed in which stable liver functionality can be maintained for several weeks to enable 
long-term studies of liver function under normal and diseased conditions.
Normal cell physiology and function strongly depend on cell-cell and cell-extracellular matrix (ECM) inter-
actions in the 3D tissue environment5. In an attempt to mimic the hepatic microenvironment, various more 
complex culture systems have been developed including sandwich cultures, and 3D models such as scaffold-based 
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systems and bioreactors6–12. However, major drawbacks of these culture systems include lack of scalability, bind-
ing of drugs to scaffold, difficulties in handling and batch-to-batch differences of ECM substrates, which affect 
reproducibility11.
To circumvent these problems, hepatocytes can be cultured as 3D microtissues termed spheroids13–16. In sphe-
roid culture, it has previously been shown that PHH can be maintained for longer periods of time with stable 
viability and production of essential molecules such as albumin and urea14–16. Furthermore, cellular polarity 
and formation of functional bile ducts has been described14. However, a full phenotypic characterization as well 
as a comprehensive assessment of the suitability of the PHH spheroid model in the context of studying e.g. liver 
diseases and chronic DILI is lacking.
Here, we have developed and extensively characterized an easily scalable 3D PHH spheroid system in 
serum-free, chemically-defined conditions, suitable for long-term functional and toxicological studies. 
Importantly, PHH spheroids closely resembled the in vivo liver tissue from where they originated more than 
spheroid cultures isolated from other donors, as determined by whole proteome analyses. Thus, inter-individual 
variability is maintained on a global scale. The PHH spheroids presented here remained phenotypically stable 
and retained morphology, viability, and hepatocyte-specific functions for culture periods of at least 5 weeks. 
The culture conditions allowed co-culture of PHH spheroids with non-parenchymal cells (NPCs) such as biliary 
cells, stellate cells and Kupffer cells and supported their long-term viability. Furthermore, liver diseases such as 
steatosis, cholestasis and viral hepatitis could be induced and the spheroids could predict chronic drug toxicity in 
particular of fialuridine, a drug which previously caused several deaths in a clinical trial while having previously 
passed all pre-clinical safety assessments17.
Combined, these results indicate that the PHH spheroid system developed here constitutes a promising and 
versatile in vitro model to study various aspects of liver function, liver disease and DILI.
Results
Characterization of PHH spheroid morphology and function. In order to constitute a relevant 
hepatic in vitro system, cultured hepatocytes need to accurately reflect phenotypes and functionality seen 
in vivo. Therefore, PHH spheroid phenotypes and their molecular signatures were assessed and compared to 
freshly isolated cells from the same donor. Once spheroids had formed and showed well-defined perimeters 
(Fig. 1A), proteomic analyses were performed using an unbiased global proteomic approach. PHH spheroids after 
aggregation (7 d 3D) and cells from the same donors that were cultured in 2D as conventional monolayers (24 h 
2D and 7 d 2D) were compared with the corresponding livers from which they originated (n = 5). Strikingly, it 
was found that proteomic signatures underwent wide-scale and rapid changes in 2D monolayer culture (Fig. 1B). 
Already after 24 h, expression of 457 proteins (13.9% of the entire detected proteome, p < 0.05, F-test) was sig-
nificantly affected. After 7 d in 2D monolayer culture, 358 proteins were differentially expressed, of which 282 
(78.8%) were already differentially expressed after 24 h.
Importantly, when the proteomes of the PHH spheroid cultures were analyzed, it was found that consider-
ably fewer proteins were differentially expressed in spheroids (n = 132) as compared to 2D monolayer culture 
(n = 358). As a consequence, hierarchical clustering (Fig. 1B) as well as principal component analysis (PCA, 
Fig. 1C) resulted in the strict separation of liver and spheroid samples from all 2D monolayer cultures. Strikingly, 
3D samples clustered together with the corresponding in vivo liver pieces they were derived from highlighting 
the preservation of inter-individual differences in PHH spheroid culture and the ability to study inter-individual 
variability in hepatic function in an in vitro system (Fig. 1D).
Next, the functional implications of the proteome alterations using gene set enrichment analyses were 
analyzed (GSEA, Fig. 1E). Interestingly, after multiple testing correction, we found that mitochondrial func-
tion (p = 1*10−13), oxidative phosphorylation (p = 1*10−11) and the TCA cycle (p = 6*10−4) were significantly 
affected only in the early stages of 2D culture (24 h), while the effect on a multitude of other important path-
ways such as glycolysis (p = 1*10−6), gluconeogenesis (p = 6*10−5), ethanol degradation (p = 7*10−3) and protein 
ubiquitination (p = 7*10−3) persisted after 7 d in 2D monolayer culture. Proteins involved in apoptosis signaling 
(p = 5*10−3) and the γ -glutamyl cycle (p = 0.04) were only found to be enriched after prolonged 2D culture 
(7 d). When analyzing the proteins that were exclusively misregulated in PHH spheroid culture, bile acid bio-
synthesis was found as the most enriched pathway (p = 0.06). Interestingly though, studies in rats have shown 
that perturbations of bile acid biosynthesis are part of the liver regeneration program in response to liver damage 
in vivo, thus suggesting that pathway perturbations seen in the PHH spheroid system closely recapitulate in vivo 
processes18.
Improvements to in vitro systems for prediction of drug metabolism and drug toxicity are needed and there-
fore the proteins involved in drug absorption, distribution, metabolism and excretion (ADME) were analyzed in 
detail. In total, 86 ADME gene products were detected in the samples. Similarly to when whole proteomes were 
considered, hierarchical clustering of ADME proteins revealed close similarities between PHH spheroid cultures 
and livers (Fig. 1F).
Combined, these results indicate that hepatic metabolism as well as intracellular signaling is highly remodeled 
in 2D monolayer cultures whereas in 3D spheroids, significantly fewer pathways were affected. Thus, as changes in 
proteomes occur very quickly even within the first 24 h, simple 2D monolayer cultures are phenotypically inferior 
to PHH spheroids even for short-term acute toxicity tests.
PHH spheroids can be stably maintained in serum-free conditions for at least 5 weeks. In 
order to assess PHH spheroid performance in long-term experiments, spheroids were characterized both mor-
phologically and functionally for 35 days in culture. Certain batches of PHH aggregated at lower efficiency and 
so a threshold for use was the requirement of good spheroid formation within 7 days. Seeding of 1,500 cells/well 
resulted in spheroids of a consistent size (~200 μ m diameter), ensuring sufficient diffusion of nutrients such as 
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oxygen to the core19. These spheroids showed homogenous morphology, clearly defined cell boundaries and intact 
nuclei without evident necrosis after 5 weeks in culture as revealed by H&E staining (Fig. 2A). During culture, 
spheroid sizes decreased coinciding with an increase in expression of the transmembrane protein E-cadherin 
Figure 1. 3D spheroids from PHH closely resemble the in vivo liver at the proteome level. (A) Time series 
showing progressing spheroid aggregation over time. Spheroid formation was judged complete after 7 d when 
a well-defined perimeter could be observed. Scale bar = 100 μ m. (B) Heatmap visualizing whole proteome 
analysis of primary human liver samples (n = 5) after 24 h and 7 d in 2D monolayer culture and spheroids after 
aggregation (7 d 3D). Only differentially expressed proteins (n = 574 proteins, p < 0.05, F-test) are shown. Note 
that in vivo liver samples (black) and spheroids (green) cluster closely together while the proteomes of samples 
cultured in 2D (24 h = blue; 7 d = red) are distinctly different. (C) Principle component analysis separates 
proteomes from liver and PHH spheroids from 2D monolayer-cultured samples. (D) In vivo phenotypes 
are preserved in 3D culture, with each of the 3D samples clustering with the respective liver piece from the 
same donor. (E) Venn diagram showing differentially regulated pathways after 24 h 2D, 7 d 2D and 7 d 3D as 
suggested by GSEA. Numbers in circles indicate numbers of differentially expressed genes compared to liver 
with p < 0.05. Extensive misregulation of a variety of important metabolic and signaling pathways is observed in 
2D such as glycolysis, gluconeogenesis, Hippo-signaling and apoptosis. In contrast, the proteomes of 3D PHH 
spheroid cultures closely resemble in vivo livers. Indicated p-values are after Benjamini-Hochberg multiple 
testing correction. (F) Heatmap showing all proteins involved in absorption, distribution, metabolism and 
excretion (ADME) of compounds that we detected in our dataset. Note that livers and PHH spheroids cultures 
cluster together, similar to when whole proteomes are considered.
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(Fig. 2B), which has been shown to play an important role in cell-cell adhesion and spheroid compaction5, sug-
gesting that spheroids become increasingly compact during the culture time. Shrinkage due to loss of hepatocytes 
during cell cultivation is also likely since staining for the apoptosis marker cleaved caspase-3 remained detectable, 
but at low levels throughout the culture period (Fig. 2C). Furthermore, MRP2 staining indicated that functional 
bile canaliculi were evident even after prolonged culture times (Fig. 2D).
Interestingly, immunohistochemical staining showed only marginal overlap of CYP3A4 (perivenous marker) 
and albumin (periportal marker) (Fig. 2E), indicating that the phenotype of cells originating from either the 
periportal or the perivenous region of the liver acinus is retained during long-term cultivation20. Cell viability 
was assessed by quantification of ATP levels which remained rather constant in relation to spheroid size (Fig. 2F) 
suggesting no decrease in viability in long-term culture.
We investigated the possibility of introducing NPCs to the spheroid system to more closely reflect the in vivo 
composition of cells present in the liver. To this end, we co-cultured PHH with a mixture of stellate, Kupffer 
and biliary cells (Fig. 3). NPCs were clearly detectable after spheroid formation. While stellate and Kupffer cells 
were detected within the spheroid, biliary cells were located on the periphery, most likely as a consequence of 
adhesion-dependent cell sorting (Fig. 3A). Markers for these cell types were also detected at the mRNA level 
(Fig. 3B). Importantly, even after prolonged culture periods NPCs present in the hepatocyte preparation remained 
detectable thus indicating that the culture conditions presented here are compatible with long-term NPC viability 
and that the number of NPCs in relation to the number of PHH remains constant (Supplementary Figure S1). 
Furthermore, LPS treatment resulted in a substantial increase in IL-6 secretion in the co-culture spheroids com-
pared to the PHH spheroids (Fig. 3C), confirming Kupffer cell activity in the spheroids. In addition, even without 
supplementing the PHH spheroids with heterologous NPCs, we observed that different preparations of cryopre-
served hepatocytes contained low numbers of NPCs, which were also present in the PHH spheroids.
PHH spheroids remain functional and metabolically active. To assess whether hepatocyte-specific 
functions were maintained in the PHH spheroids during prolonged culture, albumin secretion was analyzed and 
Figure 2. PHH spheroids can be maintained for at least 5 weeks in serum-free conditions. (A) H&E staining 
of PHH spheroids. Note that spheroid sizes decreased coinciding with increased expression of E-cadherin (B), 
which has been previously shown to promote spheroid compaction5. (C) Levels of cleaved caspase-3, a marker 
for apoptosis, remained at low levels throughout the culture period as determined by immunohistochemistry. 
(D) MRP2 immunostaining revealed bile canaliculi at early as well as late stages of spheroid culture. (E) 
Staining for the perivenous marker CYP3A4 and the periportal marker albumin reveals that the zonation-
identity of liver cells is maintained. (F) Cellular ATP levels remained constant throughout 5 weeks of culture 
(n = 20 spheroids from 3 donors per time point). Absolute ATP values were normalized to spheroid volume to 
compensate for compaction. All scale bars = 100 μ m.
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found to remain stable during prolonged culture (p = 0.51, F-test, Fig. 4A). The role of drug metabolism and the 
likely role of chemically-reactive metabolites in the toxicity of a number of compounds20 led us to investigate the 
activity of drug-metabolising enzymes in PHH spheroid culture over time. The PHH spheroids were treated with 
a cocktail of substrates for 5 major CYPs and formation of metabolites was monitored by LC-MS/MS (Fig. 4B). 
Activities of CYP1A2, CYP2D6 and CYP3A4 did not change significantly during 5 weeks of culture (p > 0.05 for all). 
In contrast, CYP2C8 activity reduced gradually and substantially to 23.5% ± 6% SEM after 5 weeks, whereas 
CYP2C9 activity increased (p < 0.05). Overall, the hepatic functions assessed in PHH spheroids were stable, 
indicating suitability for chronic drug toxicity assays.
Figure 3. PHH spheroids can be successfully co-cultured with non-parenchymal Kupffer, stellate and 
biliary cells. Immunofluorescent stainings (A) as well as qPCR analyses (B) reveal the presence of Kupffer cells 
(CD68), stellate cells (vimentin) and biliary cells (CK19) in co-cultured spheroids at day 8 (bottom row). Note 
that some PHH preparations can already contain low numbers of NPCs (top row). (C) Co-cultured Kupffer cells 
were responsive to LPS-mediated activation as evidenced by elevated IL-6 secretion.
www.nature.com/scientificreports/
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PHH spheroids are a suitable system to study chronic DILI. To investigate whether PHH spheroids 
can be used to study DILI in a more chronic setting, the toxicity of 5 hepatotoxins during up to 4 weeks of drug 
treatment was assessed. Thus, PHH spheroids were dosed every 2 days with amiodarone, bosentan, diclofenac, 
fialuridine and tolcapone, and viability was determined after 48 h, 8 and 28 days. For all 5 hepatotoxins, prolonged 
exposure led to increased toxicity and a reduction in the EC50 values by up to 1000-fold, approaching clinically 
relevant concentrations (Fig. 5). This difference was particularly evident between 48 h and 8 days. The most strik-
ing increase in toxicity during prolonged treatment was seen for fialuridine where no toxicity was observed after 
48 h, but the EC50 decreased to 100 nM after 4 weeks. This illustrates the potential of the PHH spheroids to detect 
potential hepatotoxicity for compounds previously negative in all human in vitro systems tested17. The poten-
tial for human hepatotoxicity was estimated by calculating safety margins, in which the EC50 values obtained 
in the spheroid system were related to the human plasma Cmax of each compound (amiodarone:21, bosentan:22, 
diclofenac:23, fialuridine:24, tolcapone:25). In the case of tolcapone the EC50 values decreased with prolonged expo-
sure. However the PHH spheroids were highly sensitive and the EC50 values were lower than the reported in vivo 
Cmax values already after acute dosing. Yet, in the absence of intracellular data, Cmax values can only approximate 
relevant concentrations, which might, at least partially, explain the particularly low EC50 values observed in vitro.
For the other compounds we tested, hepatotoxicity would not have been identified using a short-term 48 h 
exposure (Fig. 5F, green shading) but was clearly detected after prolonged exposures for 8 and 28 d (Fig. 5F, 
orange and red shading) using a safety margin of 3026,27. Our findings therefore suggest that the PHH spheroid 
system is a suitable model for predicting long-term in vitro toxicity.
Liver pathologies such as steatosis and cholestasis can be replicated in PHH spheroids. To 
assess whether the PHH spheroids represent a suitable system for studies of specific liver pathologies, it was 
determined whether probe drugs could induce cholestasis and steatosis. Accordingly, the PHH spheroids were 
first exposed to chlorpromazine, and significant bile acid accumulation was detected, indicating impaired bile 
Figure 4. PHH cultured as spheroids remain metabolically active for at least 5 weeks in culture.  
(A) Albumin secretion normalized to spheroid volumes during long-term spheroid culture (n = 15 spheroids 
from 3 donors per time point). (B) CYP-dependent metabolic activity of PHH spheroids over 35 days. PHH 
spheroids were exposed to a cocktail of 5 CYP substrates and the resulting metabolites were analysed via 
LC-MS/MS (n = 8 spheroids per time point). No changes in rate of drug metabolism were detected for CYP1A2, 
CYP2D6 and CYP3A4 over the course of 5 weeks (n.s. corresponds to p > 0.05, F-test), whereas CYP2C8 and 
CYP2C9 activities were found to be significantly decreased (p < 0.001) or increased (p < 0.05) respectively.
www.nature.com/scientificreports/
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acid transport, a hallmark of cholestasis (Fig. 6A,B). In line with these findings, we observed that chlorprom-
azine repressed bile salt export pump (BSEP) mRNA expression (Fig. 6C), highlighting a potential mechanism 
for this accumulation28. Furthermore, cyclosporine A treatment resulted in significant enrichment of neutral 
lipids, indicative of steatosis (Fig. 6D,E) a process strongly inhibited by the simultaneous presence of the antiox-
idant α -tocopherol29, thus suggesting that the PHH spheroid system can reproduce steatotic pathologies in vitro 
and, moreover, is suitable to study underlying disease mechanisms as well as for candidate anti-steatotic drug 
screening.
The PHH spheroid system is a useful model system for viral hepatitis. Next, it was evaluated 
whether the PHH spheroid system can be used to mimic viral hepatitis in vitro. The PHH spheroids were effi-
ciently infected by recombinant adenovirus prior to, but not after aggregation, as judged by quantifying the lumi-
nescence of spheroids infected at either day 0 upon seeding or day 4 (Fig. 7A). Introduction of the virus during 
seeding resulted in extensive GFP expression throughout the spheroid (Fig. 7B). The amount of virus was care-
fully titrated in order to ensure that spheroids were efficiently infected as judged by sufficient levels of luciferase 
expression (Fig. 7A) while being fully viable (Fig. 7C, p > 0.05 for every time point analyzed) and functional 
(Fig. 7D) even in long-term experiments.
Treatment of infected PHH spheroids with trovafloxacin, whose hepatotoxicity is amplified by inflammatory 
stimuli30, enhanced toxicity by 2.9-fold (p < 0.001), indicating virus-mediated inflammatory responses, whereas no 
toxicity of the non-hepatotoxic analogue levofloxacin was observed in both non-infected and infected spheroids.
Discussion
In vitro cellular systems are commonly used to mimic the human liver in order to perform functional and tox-
icological studies. The HepG2 and HepaRG cell lines constitute routinely used models, but the phenotype of 
these cell lines differs substantially from PHH31,32. PHH are considered the gold standard, but when maintained 
in simple 2D monolayer cultures, cells rapidly de-differentiate resulting in the loss of liver-specific functions3. 
Figure 5. PHH spheroids support chronic toxicity assays. PHH spheroids were treated with amiodarone  
(A) bosentan (B) diclofenac (C) fialuridine (D) or tolcapone (E) every second day and viability was determined 
at 48 h, 8 days and 28 days by measuring cellular ATP content (n = 5–6 spheroids per concentration and time 
point). (F) Notably, EC50 values for all compounds decreased following long-term treatment (Fold changes in 
EC50 vs. 48 h: for amiodarone: 15.4-fold (8 d) and 62.5-fold (28 d); for bosentan: 3.6-fold (8 d) and 6.0-fold  
(28 d); for diclofenac: 3.4-fold (8 d) and 4.2-fold (28 d); for fialuridine: 142.9-fold (8 d) and 1000-fold (28 d); for 
tolcapone: 2-fold (8 d) and 3.4-fold (28 d)). Safety margins were calculated in order to relate the observed EC50 
values to the physiological plasma Cmax values observed in vivo.
www.nature.com/scientificreports/
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In sandwich culture, this de-differentiation process is delayed but not prevented12,33 and it is unclear how the 
sandwich configuration affects the PHH phenotype during long-term cultures. In 3D PHH spheroid culture, the 
complex structure of the human liver is recapitulated, resulting in improved viability and various liver-specific 
functions14,15. To date, PHH spheroids have to a great extent been generated using bioreactors7,14. However, limi-
tations of these systems include the inability to control spheroid size, difficulties in handling as well as the need for 
high cell numbers. Scaffold-free spheroid formation in which spheroid size is controlled has currently only been 
performed using a hanging-drop system15. However, an extensive characterization of this system for studies of e.g. 
liver function, mechanisms of liver diseases, drug-induced liver injury (DILI) is lacking.
Unlike in previous studies14,15, the PHH spheroids presented here are maintained in chemically-defined, 
serum-free conditions. This is particularly important for toxicological studies, in which the binding of drugs 
and/or drug metabolites to serum proteins may confound the interpretation of viability data. Furthermore, the 
absence of growth factors from the media prevents the activation of extraneous cellular signaling pathways. The 
PHH spheroids described here were found to closely resemble intact liver tissues at the proteome level, using 
unbiased whole proteome profiling. In comparison to 2D monolayer cultures originating from the same livers we 
found that a multitude of important metabolic pathways were misregulated in 2D, including glycolysis, glucone-
ogenesis and the γ -glutamyl cycle, a key pathway in maintaining redox homeostasis34. Interestingly, it was found 
that even as early as after 24 h, the molecular signature of 2D monolayer-cultured hepatocytes revealed substan-
tial differences compared to liver in the overall proteome as well as in ADME proteins in particular (Fig. 1B–F). 
In contrast, we did not detect significantly misregulated pathways in the corresponding 3D spheroid cultures. 
Moreover, the hepatic phenotype is maintained during long-term culture as evidenced by sustained ATP levels 
(Fig. 2F), albumin secretion (Fig. 4A) and overall stable CYP enzyme activity (Fig. 4B).
The preserved hepatic phenotypes and long-term functionality in the PHH spheroids allowed us to test 
their versatility in chronic toxicity assays. Long-term dosing enhanced the sensitivity of PHHs to a panel of 5 
Figure 6. PHH spheroids as a model for cholestatic and steatotic disease. (A–C) Treatment with the 
cholestatic drug chlorpromazine (CPZ, 5 μ M) caused significant accumulation (n = 3, p = 0.03) of the 
fluorescently-labelled bile acid derivative tauro-nor-THCA-25-DBD, which was associated with down-
regulation of BSEP mRNA (C). (D,E) Cyclosporine A (CsA, 30 μ M), a known inducer of steatosis in vivo45 
increased levels of neutral lipids (n = 3, p = 0.003). Strikingly, cells were fully protected by co-exposure with the 
anti-oxidant α -tocopherol (α -TOH, 10 μ M) (n = 3, p = 0.009). Bile acid and lipid accumulation were quantified 
and normalized to spheroid size using CellProfiler software. All scale bars = 100 μ m. *indicates p < 0.05, 
**indicates p < 0.01.
www.nature.com/scientificreports/
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hepatotoxins (Fig. 5), thereby reflecting the delayed onset of many DILI reactions seen in vivo35. We observed 
significant reduction in the EC50 values for all compounds tested which was particularly noticeable between 48 h 
and 8 days (Fig. 5F), thus reaching toxicity in vitro at clinically relevant concentrations. This was most prominent 
for fialuridine, for which cytotoxicity was exclusively detected upon long-term dosing (EC50 > 100 μ M at 48 h vs. 
0.1 μ M at 28 days). In clinical trials, 7/15 patients developed severe hepatotoxicity, several weeks after beginning 
fialuridine treatment, five of whom died17. Despite this, no indication of fialuridine hepatotoxicity was observed 
in any pre-clinical testing. A step forward to the elucidation of its hepatotoxicity was found in chimeric TK-NOG 
mice where fialuridine induced hepatotoxicity was obtained in mice carrying human hepatocytes36. Here we 
provide a model system that is capable of predicting fialuridine toxicity in vitro, thus indicating that the PHH 
Figure 7. PHH spheroids form efficiently from virus infected hepatocytes. (A) Infection of PHH with 
recombinant adenovirus expressing GFP and luciferase (AdGL) was most effective if performed upon seeding 
(red columns; d 0) rather than when cells had aggregated into spheroids (blue columns; d 4), presumably 
due to the compactness of the spheroid at day 4 which hampers efficient penetration of the virus. All further 
experiments were performed using MOI of 0.1 due to reduced viability at higher MOIs. (B) GFP expression was 
observed throughout the spheroid. Scale bar = 100 μ m. (C) Cell viability as determined by ATP measurements 
in virus-infected spheroids was not affected at MOI = 0.1. (p > 0.05 for all time points analyzed). (D) Enzyme 
activities of 5 key CYP enzymes (n = 8 spheroids per time point). Only CYP2C9 activity after 14 d differed 
significantly (Benjamini-Hochberg correction, FDR = 0.1) compared to uninfected spheroids (compare 
Fig. 3). (E) Viral infection sensitized cells to trovafloxacin hepatotoxicity while the non-hepatotoxic analogue 
levofloxacin showed no toxicity. **indicates p < 0.01, n.s. indicates p > 0.05.
www.nature.com/scientificreports/
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spheroid model can provide a powerful tool to predict and to dissect the mechanisms underlying compound 
toxicity during pre-clinical drug development stages.
Inter-individual differences in drug response can cause severe ADRs which are a major cause of withdrawal 
of drugs from the market37. To date, only 15–30% of these inter-individual differences in response to pharma-
cological treatment can be explained38. Mechanisms for the remaining fraction of ADRs are missing due to the 
lack of suitable hepatic model systems that can successfully reflect inter-individual variability in vitro. Recent 
studies reported that inter-individual differences in CYP metabolism could be preserved using iPS-derived 
hepatocyte-like cells (HLCs) that were derived from PHH39. While interesting, this protocol has intrinsic limi-
tations as it is financially demanding, time consuming and HLCs do not reach full differentiation. Thus, here we 
considered whether PHH cultured as spheroids recapitulate inter-individual variability. Importantly, when whole 
proteomes were assessed, hierarchical clustering resulted in livers and 3D PHH spheroid cultures from the same 
donor grouping more closely together than livers from different individuals, thus indicating that inter-individual 
variation is preserved in the spheroid cultures (Fig. 1D). Therefore, the PHH spheroid system can potentially be 
used to study hepatocytes with specific genotypes of interest, which are pertinent to hereditary diseases or genetic 
variations in metabolizing enzymes with importance in drug response. In addition, by using selective antagomiR 
or siRNA-based knock-down of specific gene products in the spheroids, the role of specific genes in e.g. liver 
disease and in response to drug treatment can be studied (Supplementary Figure S2). Here we show the effective 
delivery of antagomiRs to the PHH spheroids, and an increase in CYP2C8 expression when miR103 is specifically 
targeted40.
In addition, the potential of the PHH spheroids as a model system for liver disease was assessed, focusing 
on cholestasis, steatosis and hepatitis, liver pathologies that can be the consequence of several factors, including 
exposure to certain drugs. We found that bile acid accumulation, the major hallmark of cholestasis could be 
reproduced in the PHH spheroid system after exposure to chlorpromazine (Fig. 6A,B). When proteins impor-
tant for bile transport were analyzed in detail in PHH spheroids, it was found that the bile acid pump BSEP 
(p = 0.36) and the bile exporter MRP2 (p = 0.54) were not significantly altered compared to liver tissue suggesting 
that the molecular machinery involved in bile acid circulation is preserved in spheroid culture. Chlorpromazine 
caused a major downregulation of BSEP mRNA (Fig. 6C), which indicates that the mechanisms attributed to 
chlorpromazine-induced cholestasis are reflected in the spheroid system28. To assess the suitability of PHH 
spheroids as a steatotic model system, hepatocytes were treated with cyclosporine A and a rapid enrichment 
of lipids was detected in spheroids (Fig. 6D,E). Importantly, the lipid accumulation could be prevented by 
co-treatment with α -tocopherol29. Thus, PHH spheroids constitute promising in vitro systems for the evaluation 
of drug-induced cholestasis and steatosis and enable investigations of underlying disease mechanisms, or the 
pharmacological action of new drugs. In addition, it was found that PHH spheroids can be readily infected with 
virus which renders them potentially useful for the study of liver function and toxicity in the context of viral 
infection and inflammation. Underlying viral infection is thought to be a significant risk factor for DILI, and 
both HIV and HBV infections have been associated with increased susceptibility to certain drug toxicities39,41. 
Inflammagens such as LPS and viruses can render hepatocytes more sensitive to cellular stress through toll-like 
receptor signalling and the production of inflammatory cytokines. In our system, viral infection enhanced 
trovafloxacin-induced toxicity in vitro thereby reproducing inflammation-mediated sensitization phenomena 
observed in vivo30,41.
In summary, PHH spheroids in the culture system described here were found to closely resemble in vivo 
human liver with respect to their proteomes, morphological and molecular phenotypes as well as inter-individual 
variability. They remain viable and functional over prolonged culture periods, enabling chronic exposure studies 
and facilitating drug screening for chronic DILI. In addition, we showed that the PHH spheroid system is very 
versatile and can be used to study a variety of liver diseases and DILI risk factors.
Methods
Materials. Cell culture medium, medium supplements, and compounds were obtained from Sigma-Aldrich 
(Sweden) or Life Technologies (Sweden) unless stated otherwise.
PHH spheroid cultures. Cryopreserved PHH (obtained from KalyCell, France or Bioreclamation IVT, 
USA) or fresh hepatocytes (obtained from patients subject to liver resections at Huddinge University Hospital, 
Stockholm, Sweden) were used for formation of spheroid cultures. Hepatocytes obtained from patient livers 
were isolated as previously described42. Use of the liver specimens for this purpose was approved by the Ethics 
Committee at Karolinska Institutet (Regionala etikprövningsnämnden i Stockholm) and studies were carried 
out in accordance with the approved guidelines. Written informed consent was obtained from all donors of liver 
material. Cells were seeded into ultra-low attachment 96-well plates (Corning) at 1,500 viable cells per well and 
subsequently centrifuged at 100 × g for 2 min. Cells were seeded in 100 μ l Williams E medium supplemented 
with 2 mM L-glutamine, 100 units/ml penicillin, 100 μ g/ml streptomycin, 10 μ g/ml insulin, 5.5 μ g/ml transferrin, 
6.7 ng/ml sodium selenite, 100 nM dexamethasone, and 10% FBS. Spontaneous self-aggregation of the hepato-
cytes initiated spheroid formation. From day 4 or 5 after seeding, when the spheroids were sufficiently compact, 
50% of the medium was exchanged daily for serum-free medium. Spheroids were maintained in serum-free 
medium until day 35, with a medium change every 48–72 h.
Co-culture spheroids. When used, co-cultures of cryopreserved PHH and non-parenchymal cells (NPCs; 
Bioreclamation IVT) originating from different donors were thawed and seeded at a ratio of 2:1 (PHH:NPC) 
and 2,000 viable cells per well into ultra-low attachment plates. Functionality of Kupffer cells was assessed by 
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measuring lipopolysaccharide (LPS)-induced interleukin 6 (IL-6) secretion. LPS was added at a concentration of 
10 μ g/ml and supernatants were collected after 48 h. IL-6 levels were determined via ELISA (Thermo Scientific).
Proteomics. Freshly isolated PHH were compared to liver tissue, 3D PHH spheroids after aggregation (7 d) 
and cells cultured as 2D monolayers (24 h and 7 d) from the same donors. Cells were washed, scraped and pelleted 
in phosphate buffer (pH 7.4). Subsequently, cells were resuspended in a volume of 0.5 M TEAB/0.1% SDS equiva-
lent to cell pellet volume. Liver samples (50–100 mg) were homogenised in 0.5 M TEAB/0.1% SDS using a Mixer 
Mill 220 (Retsch, Haan, Germany). Cell and liver samples were subjected to one freeze-thaw cycle, sonicated 
and centrifuged. 100 μ g protein/sample were denatured, reduced and treated with methyl methanethiosulfonate 
according to the manufacturer’s protocol (Sciex, Framingham, MA, USA), before being labelled with isobaric tags 
for absolute and relative quantification (iTRAQ), pre-fractionated by cation exchange chromatography and ana-
lysed on a Triple TOF 5600 (Sciex) as previously described43. Samples from each donor were analysed in a single 
iTRAQ run. Data were searched using ProteinPilot 4.2 and the Paragon algorithm (Sciex) against the SwissProt 
database and a reversed decoy database and only proteins lying within a 1% global false discovery rate (FDR) were 
taken forward for analysis.
Statistical analysis. Principle component analyses were computed using Qlucore Omics Explorer 3.1. To 
this end, only proteins whose abundances were significantly different (p < 0.05, F-test) between the different time 
points were considered. Hierarchical clustering was performed on mean-centered sigma-normalized protein lev-
els using maximum linkage in Qlucore Omics Explorer 3.1. Gene set enrichment analysis was performed using 
Ingenuity Pathway Analysis (Qiagen, Sollentuna, Sweden).
Deviations from linearity were calculated using F-tests (Prism, GraphPad Software, USA). For two-group 
comparisons, heteroscedastic Student’s t-tests were calculated in Excel (Microsoft). When numbers of tests 
exceeded 10, multiple testing corrections were employed using the Benjamini-Hochberg procedure with false 
discovery rates of 5% or as indicated.
Immunohistochemistry. Spheroids were collected, fixed with 4% formaldehyde for 24 h, cryoprotected 
in 30% sucrose and embedded in Tissue-Tek OCT compound (Sakura, The Netherlands). Spheroid cryosec-
tions (8 μ m) were stained for CYP3A4 (PAP011, 1:5,000, Cypex Limited, United Kingdom), albumin (sc51515, 
1:200, Santa Cruz, USA), E-cadherin (13–1700, 1:300, Thermo Scientific), MRP2 (ab3373, 1:100, Abcam, United 
Kingdom), CK19 (sc6278, 1:100, Santa Cruz), CD68 (sc70761, 1:50, Santa Cruz), Cleaved caspase-3 (9661, 1:500, 
Cell Signaling Technology, USA) and Vimentin (ab92547, 1:200, Abcam). CellProfiler software was used to quan-
tify marker staining relative to spheroid size.
Assesment of viability and albumin secretion. Cell viability was assessed by determining the ATP 
content of single PHH spheroids with the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Sweden). 
At the same time-points, cell culture medium was collected and albumin concentrations were determined by 
ELISA (Bethyl laboratories, USA). Absolute ATP and albumin values were normalized to spheroid volumes as 
determined from bright field imaging to compensate for compaction.
Determination of CYP450 enzyme metabolic activity. PHH spheroids were incubated with a mix-
ture of probe substrates, i.e. midazolam (CYP3A4, 10 μ M), dextromethorphan (CYP2D6, 15 μ M), phenacetin 
(CYP1A2, 100 μ M), amodiaquine (CYP2C8, 10 μ M) and tolbutamide (CYP2C9, 100 μ M) and supernatants were 
collected after 24 h. Formed metabolites (1-OH-midazolam, dextrorphan, acetaminophen, desethyl-amodiaquine 
and OH-tolbutamide) were quantified by LC/MS-MS. Deuterated 1-OH midazolam was added as an internal 
standard. For all metabolites but OH-tolbutamide, a mobile phase starting with solvent A (5% acetonitrile, 0.1% 
CH3OOH) shifting to solvent B (95% acetonitrile, 0.1% CH3OOH) using a linear gradient was pumped at a flow 
rate of 0.6 ml/min. Separation was carried out using an Acquity UPLC C18 column and eluted fractions were 
directly passed through a Xevo TQ-S tandem mass spectrometer (both from Waters Corp., Milford, MA, US) 
equipped with an electrospray ionization source operating in the positive ion mode. For OH-tolbutamide, a 
mobile phase starting with solvent A (4% methanol, 0.1% formic acid) shifting to solvent B (95% methanol, 0.1% 
formic acid) shifting back to solvent A was used and the tandem mass spectrometer was operated in the negative 
ion mode. Acquired data were processed with Thermo Xcaliber software (Thermo Scientific, Waltham, MA, US). 
All results are expressed as measurements from single spheroids. An overview of mass transition for CYP450 
probe substrates is given in Supplementary Table 1.
Toxicity assays. Stock solutions of amiodarone, bosentan (Sequoia, St. Louis, MO, USA), diclofenac, fialuri-
dine (Carbosynth, Berkshire, UK) and tolcapone were diluted in serum-free medium to a maximal final DMSO 
concentration of 0.4%. Treatment was started on day 8 with repeated dosing of PHH spheroids every second 
day in serum-free medium as indicated. Cell viability was assessed by determining the ATP content as indicated 
above. EC50 values were determined using GraphPad Prism (GraphPad Software, USA).
Bile acid accumulation. PHH spheroids were dosed with 5 μ M chlorpromazine every second day for 1 
week. For the final exposure, 20 μ M tauro-nor-THCA-25-DBD (Genomembrane Company Ltd., Yokohoma, 
Japan) was added. Bile acid accumulation was quantified and normalized to spheroid size using CellProfiler 
software.
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RT-qPCR analysis. Total RNA was isolated using Qiazol lysis reagent (Qiagen). RNA was reverse-transcribed 
into cDNA using SuperScript III reverse transcriptase and RT-qPCR analysis was performed using a TaqMan 
Universal mix on a 7500 Fast Real-Time PCR system.
Neutral lipid staining. PHH spheroids were treated with 30 μ M cyclosporine A (CsA) and/or 10 μ M 
α -tocopherol (α -TOH) as indicated. After 48 h, spheroids were fixed and incubated with HCS LipidTOX Green 
neutral lipid stain (1:500). CellProfiler software was used to quantify neutral lipid staining.
Viral infection of spheroids. A recombinant adenovirus (AdGL) expressing green fluorescent protein 
(GFP; described in ref. 44) was added during PHH spheroid seeding at a multiplicity of infection (MOI) of 0.1. 
PHH were seeded into GravityPLUS hanging-drop 96-well plates (InSphero, Zurich, Switzerland) at 1,500 viable 
cells per well. Spheroids were transferred to Gravity TRAP 96-well plates (InSphero) on day 7. Culture conditions 
were identical to the conditions for spheroids formed in ultra-low attachment plates.
Confocal imaging. All fluorescent images were acquired using an LSM710 confocal microscope (Zeiss, 
Germany). Images were processed with ZEN lite 2012 analysis software (Zeiss, Germany).
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